Atlast Bio: Swiss AI drug trial startup receives funding from Spotify
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Swiss AI startup Atlast Bio got $12.5 million in funding led by Creandum on Tuesday.
- ✓The company uses an AI model trained on two million human RNA readouts to run virtual drug trials.
- ✓This new method aims to replace animal testing and long trials, with first results expected within 6 weeks.
Story at a Glance
- Category
- BUSINESS
- Reported By
- The Economic Times
- Reading Speed
- 1 Minute(s)
- Market Focus
- India Economy
Synopsis
An AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said.
Listen to this article in summarized format
ZURICH: Swiss AI start-up Atlast Bio, which runs drug trials on virtual patients, has received $12.5 million in funding led by Swedish venture capital firm Creandum, an early backer of Spotify and Trade Republic, the company said on Tuesday.
* Atlas Bio is aiming to replace Phase II drug trials, which it says cost more than $100 million, take two to three years and see about 70% of drugs fail at that stage
* An AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
The Economic Times
Read the full, original unfiltered story directly on the publisher's portal.